Given the tumor heterogeneity in the immune microenvironment of HNSC, we hypothesized that some immune-associated signatures influenced by TP53 mutations might play crucial roles in assessing prognosis and therapeutic responses and even guiding clinical treatment for HNSC. This evidence concerns the gene TP53 and neoplasm.